In particular, the study demonstrated the ability of the Notch4 inhibitor RO4929097 to reverse the acquisition of resistance to tamoxifen and fulvestrant treatment in breast cancer cells dissociated from PDX after long-term treatment with antiestrogens [61]. This evidence concerns the gene NOTCH4 and breast carcinoma.